Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With RCC vs Patients Without RCC
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersOBJECTIVE
This systematic review and meta-analysis was accomplished with the purpose of evaluating the risk of encountering selected hair changes in patients with cancer receiving pazopanib.
METHODS
We favored relevant prospective randomized phase II and III trials that assessed pazopanib in patients with cancer, depicting various hair-related changes, as eligible for inclusion.
RESULTS
After elimination of ineligible studies, a total of 11 clinical trials were regarded as eligible for the meta-analysis. The relative risk of all-grade alopecia and hair color changes was 1.75 (95% confidence interval, 1.33-2.31; P < .0001) and 4.54 (95% confidence interval, 3.67-5.62; P < .00001), respectively. Subgroup analyses of hair color changes according to the type of cancer treated revealed significant differences between renal cell carcinoma and non-renal cell carcinoma studies (P = .01).
CONCLUSIONS
Our meta-analysis has established that pazopanib-based treatment can be significantly correlated to an elevated risk of all grade alopecia and hair color changes compared with controls.
Additional Info
Disclosure statements are available on the authors' profiles:
Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis
Clin Genitourin Cancer 2017 Jan 13;[EPub Ahead of Print], H Elhalawani, M Heiba, O Abdel-RahmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.
Educating cancer patients on hair and skin changes during cancer-related therapy is not a new concept for oncology nurses. The hair changes associated with pazopanib for RCC patients is yet another side effect oncology nurses need to be prepared to discuss with their patients, ranging from likelihood of incidence to mechanism of action, as discussed in this thorough review article entitled “Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis.” In this study, the relative risk of all-grade alopecia was 1.75 (95% confidence interval, 1.33-2.31; P < .0001) and of hair color change was 4.54 (95% confidence interval, 3.67-5.62; P < .00001). Oncology nurses have been traditionally well versed in coaching and soothing patients that suffer from the physical and psychological effects that traditional cytotoxic chemotherapy yields on skin and hair. This article serves to bolster this skill even further when it comes to educating patients who are taking pazopanib for renal cell carcinoma.